Key Takeaways
- • Ned Sharpless appointed Managing Director of Hatteras Discovery Innovation, a revived early-stage biotech company-creation strategy within Hatteras Venture Partners, positioned to provide seed-stage funding to emerging life sciences startups.
- • Andrew Witty returns as Chairman of Hatteras Venture Partners, the former CEO of GlaxoSmithKline and UnitedHealth Group, bringing deep pharmaceutical and healthcare industry experience to lead the firm's strategic direction.
- • Hatteras Venture Partners has backed 100 life sciences startups and is now reinvigorating its early-stage discovery and innovation strategy through this leadership realignment, based in North Carolina.
- • Sharpless brings oncology, scientific, and public-sector credentials as a former National Cancer Institute leader and accomplished oncologist, positioning him to lead next-generation company creation in biotech.
Summary
Hatteras Venture Partners announced a significant leadership realignment on September 30, 2026, appointing Ned Sharpless as Managing Director of its revived Hatteras Discovery Innovation platform while welcoming back Sir Andrew Witty as Chairman. This restructuring signals the firm's renewed commitment to early-stage biotechnology company creation and seed-stage funding in life sciences.
Sharpless, an accomplished oncologist and former leader at the National Cancer Institute, assumes responsibility for Hatteras Discovery Innovation, which serves as the firm's primary vehicle for providing first-check capital to seed-stage biotech companies. His clinical background and experience navigating both private sector innovation and public health leadership position him to identify and nurture emerging therapeutic opportunities at their earliest stages.
Andrew Witty's return to the firm as Chairman reinforces this strategic pivot. Witty brings extensive pharmaceutical and healthcare sector expertise accumulated through his tenure as CEO of GlaxoSmithKline and subsequent leadership at UnitedHealth Group. His appointment combines operational knowledge of large-scale drug development with investment acumen, establishing a leadership duo capable of bridging discovery-stage science with commercialization pathways.
Hatteras Venture Partners has established a track record of backing 100 life sciences startups, demonstrating sustained commitment to the biotech ecosystem. The firm's North Carolina base positions it within an emerging life sciences hub, potentially enhancing its ability to source and support early-stage companies in the region. This leadership structure and resource allocation reflect confidence in near-term opportunities within biotechnology, particularly at the discovery and seed-stage segments where capital availability and experienced guidance remain competitive advantages.
Sharpless, an accomplished oncologist and former leader at the National Cancer Institute, assumes responsibility for Hatteras Discovery Innovation, which serves as the firm's primary vehicle for providing first-check capital to seed-stage biotech companies. His clinical background and experience navigating both private sector innovation and public health leadership position him to identify and nurture emerging therapeutic opportunities at their earliest stages.
Andrew Witty's return to the firm as Chairman reinforces this strategic pivot. Witty brings extensive pharmaceutical and healthcare sector expertise accumulated through his tenure as CEO of GlaxoSmithKline and subsequent leadership at UnitedHealth Group. His appointment combines operational knowledge of large-scale drug development with investment acumen, establishing a leadership duo capable of bridging discovery-stage science with commercialization pathways.
Hatteras Venture Partners has established a track record of backing 100 life sciences startups, demonstrating sustained commitment to the biotech ecosystem. The firm's North Carolina base positions it within an emerging life sciences hub, potentially enhancing its ability to source and support early-stage companies in the region. This leadership structure and resource allocation reflect confidence in near-term opportunities within biotechnology, particularly at the discovery and seed-stage segments where capital availability and experienced guidance remain competitive advantages.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.